MUSCAT: Pharmaceutical giant AstraZeneca has “voluntarily paused” a clinical trial of its coronavirus vaccine after a volunteer developed an unexplained illness.
The company, which is developing the drug alongside the University of Oxford in the UK, is a frontrunner in the global race for a COVID-19 vaccine.
“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee,” a spokesperson said.
Read More
- Oman participates in London Press Club awards, presents Journalist of the Year honours
- His Majesty Sultan Haitham concludes UK state visit as investment and trade ties deepen
- Oman Meteorology: Moderate chance of tropical activity in Arabian Sea, no direct impact expected
- Oman’s TRA to host public dialogue on child online safety
- His Majesty Sultan Haitham meets company executives, reviews innovative projects
“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline,” the spokesperson added.
